A committee of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend Moderna's new mRNA influenza vaccine for adults aged 50 and older. All nine members of the committee participated in the vote.
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over
The FDA committee has unanimously recommended Moderna's mRNA influenza vaccine for adults aged 50 and over. This marks the first vaccine recommendation by the committee since 2023.
Companies
Moderna
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
Key FDA committee unanimously recommends its first vaccine since 2023
Neutral Headline
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over